Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Davies, Anna ^a   Singh, Kasha P ^b,c   Shubber, Zara ^a   duCros, Philipp ^d   Mills, Edward J ^e   Cooke, Graham ^a   Ford, Nathan ^a,d,f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; META ANALYSIS; MIXED INFECTION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; COINFECTION; GENOTYPE; HEPATITIS C; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84873510483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055373     Document Type: Article

References (58)

1. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054-1058.
2. Rockstroh J, Konopnicki D, Soriano V (2004) Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, Feb 8-11. Abstract 799.
3. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS (2010) A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 8: 280-288, 288 e281.
4. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, et al. (2012) Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA: the journal of the American Medical Association 308: 370-378.
5. Durier N, Nguyen C, White LJ, (2012) Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PloS one 7: e34548.
6. Iorio A, Marchesini E, Awad T, Gluud LL (2010) Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane database of systematic reviews: CD004888.
7. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, et al. (2012) Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bulletin of the World Health Organization 90: 540-550.
8. Vandenbroucke JP, (2011) Why do the results of randomised and observational studies differ? BMJ 343: d7020.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
10. Freeman MF, Tukey J, (1950) Transformations related to the angular and the square root. Ann Inst Stat Mathematics 21: 607-611.
11. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Controlled clinical trials 7: 177-188.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
13. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, Tettoni C, Bonasso M, et al. (2008) The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. The Journal of antimicrobial chemotherapy 61: 919-924.
14. Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, et al. (2010) The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antiviral therapy 15: 91-99.
15. Araujo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, et al. (2011) Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. Journal of viral hepatitis 18: e52-60.
16. Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, et al. (2009) Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. Journal of acquired immune deficiency syndromes 52: 452-458.
17. Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, et al. (2011) Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. The Journal of antimicrobial chemotherapy 66: 2843-2849.
18. Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, et al. (2010) Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients. The Journal of infectious diseases 202: 894-898.
19. Cesari M, Caramma I, Antinori S, Adorni F, Galli M, et al. (2009) Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients. HIV medicine 10: 580-585.
20. Cooper CL, Giordano C, Mackie D, Mills EJ, (2010) Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Therapeutics and clinical risk management 6: 207-212.
21. Fleming CA, Tumilty S, Murray JE, Nunes D, (2005) Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 40Suppl 5: S349-354.
22. Gonvers JJ, Heim MH, Cavassini M, Mullhaupt B, Genne D, et al. (2010) Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Swiss medical weekly 140: w13055.
23. James PD, Wong DKH, (2008) Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment. Canadian Journal of Infectious Diseases and Medical Microbiology 23: 31-35.
24. Karlstrom O, Sonnerborg A, Weiland O, (2008) Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy. AIDS 22: 899-901.
25. Kieran J, Dillon A, Farrell G, Jackson A, Norris S, et al. (2011) High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. International journal of STD & AIDS 22: 571-576.
26. Laufer N, Bolcic F, Rolon MJ, Martinez A, Reynoso R, et al. (2011) HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antiviral research 90: 92-97.
27. Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C, (2010) Sustained virological response according to the type of early virological response in HCV and HCV/HIV. Annals of hepatology 9: 150-155.
28. Lopez-Cortes LF, Ruiz-Valderas R, Jimenez-Jimenez L, Gonzalez-Escribano MF, Torres-Cornejo A, et al. (2012) Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-alpha 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. PloS one 7: e28115.
29. Macias J, del Valle J, Rivero A, Mira JA, Camacho A, et al. (2010) Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. The Journal of antimicrobial chemotherapy 65: 2204-2211.
30. Marchetti G, Nasta P, Bai F, Gatti F, Bellistri GM, et al. (2012) Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PloS one 7: e32028.
31. Maru DS, Bruce RD, Basu S, Altice FL, (2008) Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 47: 952-961.
32. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, et al. (2006) Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 20: 2361-2369.
33. Michielsen P, Bottieau E, Van Vlierberghe H, Van Marck E, Vandemaele E, et al. (2009) Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study. Acta gastro-enterologica Belgica 72: 389-393.
34. Mira JA, Gutierrez-Valencia A, Gil Ide L, Merino D, Rivero A, et al. (2009) Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 49: e84-91.
35. Murray MC, Barrios R, Zhang W, Hull M, Montessori V, et al. (2011) Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. European journal of gastroenterology & hepatology 23: 45-50.
36. Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, et al. (2001) Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS 15: 1783-1787.
37. Neukam K, Camacho A, Caruz A, Rallon N, Torres-Cornejo A, et al. (2012) Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Journal of hepatology 56: 788-794.
38. Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Saune K, et al. (2008) Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. Journal of medical virology 80: 1523-1529.
39. Nischalke HD, Vogel M, Mauss S, Baumgarten A, Lutz T, et al. (2010) The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection. AIDS 24: 2001-2007.
40. Poizot-Martin I, Marimoutou C, Benhaim S, Drogoul-Vey MP, Dinh T, et al. (2003) Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment. HIV clinical trials 4: 262-268.
41. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, et al. (2008) IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antiviral therapy 13: 969-976.
42. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, et al. (2011) Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antiviral therapy 16: 815-824.
43. Righi E, Beltrame A, Bassetti M, Lindstrom V, Mazzarello G, et al. (2008) Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection 36: 358-361.
44. Sacchi A, Agrati C, D'Offizi G, Vlassi C, Rozera G, et al. (2011) The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. Clinical immunology 138: 178-186.
45. Santin M, Shaw E, Garcia MJ, Delejido A, de Castro ER, et al. (2006) Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS research and human retroviruses 22: 315-320.
46. Sarmento-Castro R, Horta A, Vasconcelos O, Coelho H, Mendez J, et al. (2007) Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection. The Journal of infection 54: 609-616.
47. Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, et al. (2011) Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug and alcohol dependence 116: 233-237.
48. Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, et al. (2007) Improved cognitive function as a consequence of hepatitis C virus treatment. HIV medicine 8: 520-528.
49. Van den Eynde E, Tiraboschi JM, Tural C, Sola R, Mira JA, et al. (2010) Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS 24: 975-982.
50. Wagner G, Chan Osilla K, Garnett J, Ghosh-Dastidar B, Bhatti L, et al. (2011) Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS research and treatment 2011: 903480.
51. Yotsuyanagi H, Kikuchi Y, Tsukada K, Nishida K, Kato M, et al. (2009) Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: a retrospective multicenter analysis. Hepatology research: the official journal of the Japan Society of Hepatology 39: 657-663.
52. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, et al. (2006) Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy 11: 131-142.
53. Bedossa P, Poynard T, (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293.
54. Mitchell AE, Colvin HM, Palmer Beasley R, (2010) Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 51: 729-733.
55. Scaglione SJ, Lok AS (2012) Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142: 1360-1368 e1361.
56. Gluud LL, Marchesini E, Iorio A (2009) Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. The American journal of gastroenterology 104: 2335-2341; quiz 2342.
57. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, et al. (2002) Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16: 1915-1923.
58. Medrano J, Barreiro P, Resino S, Tuma P, Rodriguez V, et al. (2009) Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 49: 1397-1401.